Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2009-015100-25-FR
EUCTR2009-015100-25-FR
Active, not recruiting
Not Applicable

Cohorte multicentrique nationale de patients atteints de grippe pandémique(nouveau virus A/H1N1v d’origine porcine) - Etude Flu Co

INSERM0 sites1,500 target enrollmentNovember 27, 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsRibavirine 200 mg (28 comprimés)OseltamivirZanamivir 20mg (20 unidoses)Zanamivir 20mg (4 unidoses)AmantadineRibavirine 200mg (84 gélules)Ribavirine 200mg (112 gélules)Ribavirine 200mg (140 gélules)Ribavirine 200mg (168 gélules)RibavirineRibavirine 400mg (14 comprimés)Ribavirine 400 mg (56 comprimés)Ribavirine 200 mg (42 comprimés)Ribavirine 200mg (112 comprimés)Ribavirine 200mg (168 comprimés)

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
INSERM
Enrollment
1500
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 27, 2009
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
INSERM

Eligibility Criteria

Inclusion Criteria

  • •Eligibilité : diagnostic clinique d’un syndrome grippal (cas possibles définis par l’INVS), consentement signé
  • •Inclusion : diagnostic de grippe A/H1N1v confirmé par RT\-PCR
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •Non applicable

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
ENSAYO CLÍNICO MULTICÉNTRICO, MULTINACIONAL, ABIERTO, ALEATORIZADO, CON GRUPOS PARALELOS DE TOBRINEB®/ACTITOB®/ BRAMITOB® (TOBRAMICINA SOLUCIÓN PARA NEBULIZACIÓN, 300 mg DOS VECES AL DÍA EN VIALES UNIDOSIS DE 4 ML) EN COMPARACIÓN CON TOBI® EN EL TRATAMIENTO DE PACIENTES CON FIBROSIS QUÍSTICA E INFECCIÓN CRÓNICA POR PSEUDOMONAS AERUGINOSA
EUCTR2006-006215-68-ESChiesi Farmaceutici S.p.A324
Active, not recruiting
Not Applicable
Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease
EUCTR2005-002088-98-ATAmarin Neuroscience Ltd240
Active, not recruiting
Not Applicable
Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s DiseaseHUNTINGTON’S DISEASEMedDRA version: 8.0Level: LLTClassification code 10010331
EUCTR2005-002088-98-PTAmarin Neuroscience Ltd
Active, not recruiting
Not Applicable
Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s DiseaseHUNTINGTON’S DISEASEMedDRA version: 8.0Level: LLTClassification code 10010331
EUCTR2005-002088-98-GBAmarin Neuroscience Ltd
Active, not recruiting
Not Applicable
Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease
EUCTR2005-002088-98-DEAmarin Neuroscience Ltd240